Brief: Jazz Pharmaceuticals And Werewolf Therapeutics Announce Exclusive Global License And Collaboration Agreement To Develop Wtx-613, A Differentiated, Conditionally-Activated IFNα Indukine Molecule

Werewolf Therapeutics

07/04/2022 12:18

April 7 (Reuters) - Werewolf Therapeutics Inc  HOWL.O :
    * JAZZ PHARMACEUTICALS AND WEREWOLF THERAPEUTICS ANNOUNCE
EXCLUSIVE GLOBAL LICENSE AND COLLABORATION AGREEMENT TO DEVELOP
WTX-613, A DIFFERENTIATED, CONDITIONALLY-ACTIVATED IFNΑ
INDUKINE™ MOLECULE
    * WEREWOLF THERAPEUTICS INC - TO RECEIVE $15 MILLION UPFRONT
PAYMENT, WITH POTENTIAL FOR UP TO $1.26 BILLION
    * WEREWOLF THERAPEUTICS INC - UNDER TERMS OF TRANSACTION,
JAZZ HAS
SECURED EXCLUSIVE GLOBAL RIGHTS TO WTX-613
    * WEREWOLF THERAPEUTICS INC - PENDING APPROVAL, WEREWOLF IS
ELIGIBLE TO RECEIVE A TIERED, MID-SINGLE-DIGIT PERCENTAGE
ROYALTY ON NET SALES OF WTX-613

Source text for Eikon:  ID:nPn1fLzCRa 
Further company coverage:  HOWL.O 

 ((Reuters.Briefs@thomsonreuters.com;))